Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Cabral-Marques O, Moll G, Catar R, Preuß B, Bankamp L, Pecher AC, Henes J, Klein R, Kamalanathan AS, Akbarzadeh R, van Oostveen W, Hohberger B, Endres M, Koolmoes B, Levarht N, Postma R, van Duinen V, van Zonneveld AJ, de Vries-Bouwstra J, Fehres C, Tran F, do Vale FYN, da Silva Souza KB, Filgueiras IS, Schimke LF, Baiocchi GC, de Miranda GC, da Fonseca DLM, Freire PP, Hackel AM, Grasshoff H, Stähle A, Müller A, Dechend R, Yu X, Petersen F, Sotzny F, Sakmar TP, Ochs HD, Schulze-Forster K, Heidecke H, Scheibenbogen C, Shoenfeld Y, Riemekasten G (2023)

Publication Type: Journal article, Review article

Publication year: 2023

Journal

Autoimmunity Reviews Elsevier

Book Volume: 22

Article Number: 103310

Journal Issue: 5

DOI: 10.1016/j.autrev.2023.103310

Abstract

G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

Authors with CRIS profile

Bettina Hohberger Department of Ophthalmology

Involved external institutions

University of São Paulo / Universidade de São Paulo (USP) BR Brazil (BR) Charité - Universitätsmedizin Berlin DE Germany (DE) Eberhard Karls Universität Tübingen DE Germany (DE) Universität zu Lübeck DE Germany (DE) Leiden University Medical Center NL Netherlands (NL) Christian-Albrechts-Universität zu Kiel DE Germany (DE) Max-Delbrück-Centrum für Molekulare Medizin / Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch DE Germany (DE) Forschungszentrum Borstel - Leibniz-Zentrum für Medizin und Biowissenschaften / Research Center Borstel - Leibniz-Center for Medicine and Biosciences DE Germany (DE) VIT University (Vellore Institute of Technology) IN India (IN) Rockefeller University US United States (USA) (US) University of Washington US United States (USA) (US) CellTrend GmbH DE Germany (DE) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ IL Israel (IL)

How to cite

APA:

Cabral-Marques, O., Moll, G., Catar, R., Preuß, B., Bankamp, L., Pecher, A.C.,... Riemekasten, G. (2023). Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. Autoimmunity Reviews, 22(5). https://dx.doi.org/10.1016/j.autrev.2023.103310

MLA:

Cabral-Marques, Otávio, et al. "Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium." Autoimmunity Reviews 22.5 (2023).

BibTeX: Download